Merck’s Keytruda (pembrolizumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma (HCC)
Shots:
- The KEYNOTE-224 study involves assessing of Keytruda (200mg q3w @24mos) in 104 patients with HCC aged ≥65, previously treated or intolerant to sorafenib
- KEYNOTE-224 study results: ECOG PS 0 or 1 (61% or 39%); Child Pugh class A5/A6/B7/B8 (72%/22%/5%/1%); HBV & HCV seropositive (21% & 25%); ORR (17%); CR (1%); PR (16%); mDOR @ 6mos.&12mos. (89% & 56%)
- Keytruda is a mAb, works as an anti-PD -1 therapy for tumor cells and has received 14 approvals including one for HCC & is evaluated in > 850 trials in for different cancers
Click here to read full press release/ article | Ref: Merck | Image: Chemistry World